Compare QDEL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | PHVS |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | QDEL | PHVS |
|---|---|---|
| Price | $29.38 | $26.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $39.33 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 857.8K | 475.7K |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,714,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.50 | $11.51 |
| 52 Week High | $49.45 | $29.80 |
| Indicator | QDEL | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 53.90 |
| Support Level | $28.39 | $25.27 |
| Resistance Level | $29.62 | $26.09 |
| Average True Range (ATR) | 1.16 | 1.20 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 67.00 | 66.98 |
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.